LakeShore Biopharma Co., Ltd (LSB)
Automate Your Wheel Strategy on LSB
With Tiblio's Option Bot, you can configure your own wheel strategy including LSB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LSB
- Rev/Share 0.0
- Book/Share 0.0
- PB 0.0
- Debt/Equity 0.8292
- CurrentRatio 1.0212
- ROIC -0.0915
- MktCap 241566804.657
- FreeCF/Share 0.0
- PFCF -1.7399
- PE 0.0
- Debt/Assets 0.303
- DivYield 0
- ROE -0.1843
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
BEIJING , Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter (the "Proposal Letter"), dated August 18, 2025, from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. (collectively, "Oceanpine Capital") to acquire all of the outstanding ordinary shares, par value US$0.0002 per share, of the Company (the "Ordinary Shares") that are not currently …
Read More
LakeShore Biopharma Announces Fiscal Year 2025 Financial Results
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
Total revenue reached RMB615.0 million, representing 7.2% year-over-year growth Gross profit rose to RMB507.2 million, up 11.3% year-over-year Gross margin improved to 82.5% from 79.5% in Fiscal Year 2024 Total operating expenses decreased 34.2% year-over-year to RMB593.5 million EBITDA[1] and Adjusted EBITDA[2] were RMB(48.5 million) and RMB0.6 million, respectively, compared to RMB(368.7 million) and RMB(236.4 million) in Fiscal Year 2024 Net loss narrowed to RMB100.0 million, with an adjusted net loss[3] of RMB40.0 million, compared to RMB433.5 million and RMB266.3 million, respectively, in Fiscal Year 2024 BEIJING , July 31, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore …
Read More
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
Published: April 23, 2025 by: PRNewsWire
Sentiment: Neutral
Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING , April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province.
Read More
About LakeShore Biopharma Co., Ltd (LSB)
- IPO Date 2021-08-05
- Website https://www.ysbiopharm.com
- Industry Biotechnology
- CEO Wang Xu
- Employees 758